Chipscreen(SH:688321)2025-04-25 11:10Financial Performance - The company's revenue for Q1 2025 was CNY 162.26 million, representing a 24.24% increase compared to CNY 130.60 million in the same period last year[2]. - The net profit attributable to shareholders was a loss of CNY 19.15 million, slightly worsening from a loss of CNY 18.30 million year-over-year, reflecting a 4.64% increase in losses[2]. - The diluted earnings per share for the quarter was CNY -0.0470, compared to CNY -0.0448 in the same period last year, reflecting a 4.91% increase in losses per share[3]. - Net loss for Q1 2025 was ¥19.15 million, compared to a net loss of ¥18.30 million in Q1 2024, reflecting a 4.6% increase in losses[14]. - Other comprehensive income after tax for Q1 2025 was -¥81.68 million, contrasting with a positive amount of ¥112.70 million in Q1 2024[14]. Cash Flow - The net cash flow from operating activities decreased by 43.60%, down to CNY 19.98 million from CNY 35.43 million in the previous year, primarily due to increased material purchases and operating expenses[5]. - Cash flow from operating activities for Q1 2025 was ¥19.98 million, down 43.5% from ¥35.43 million in Q1 2024[16]. - Cash flow from investing activities showed a net outflow of ¥57.11 million in Q1 2025, compared to a net inflow of ¥25.47 million in Q1 2024[16]. - Cash flow from financing activities generated a net inflow of ¥58.56 million in Q1 2025, an increase from ¥33.41 million in Q1 2024[17]. - The ending cash and cash equivalents balance for Q1 2025 was ¥243.83 million, down from ¥361.16 million at the end of Q1 2024[17]. Research and Development - Research and development expenses totaled CNY 73.05 million, accounting for 45.02% of revenue, down from 61.41% in the previous year, indicating a decrease of 16.39 percentage points[3]. - Research and development expenses for Q1 2025 were ¥52.91 million, slightly up from ¥52.50 million in Q1 2024[13]. Assets and Liabilities - Total assets increased by 1.87% to CNY 3.31 billion from CNY 3.25 billion at the end of the previous year[3]. - The company's total current assets reached RMB 1,134,827,622.72, up from RMB 1,083,471,551.64, indicating an increase of about 4.71%[10]. - The company's inventory increased to RMB 50,753,968.26 from RMB 40,843,656.94, representing a growth of around 24.5%[10]. - Total liabilities rose to RMB 1,749,840,730.61 from RMB 1,669,800,309.41, marking an increase of about 4.79%[11]. - The company's total equity decreased to RMB 1,561,862,397.76 from RMB 1,581,098,748.77, a decline of approximately 1.22%[11]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,684[6]. - The largest shareholder, Boao Biological Group Co., Ltd., holds 34,705,162 shares, representing 8.51% of the total shares[7]. Government Subsidies - The company received government subsidies amounting to CNY 5.60 million, which positively impacted its financial performance[4].